Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.63 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | HNF4A | P41235 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30477514 | 1.00 | TRPA1 (0.63) | TRPA1CA1CA2CA12CA7 | |
| SCHEMBL1647970 | 1.00 | TRPA1 (0.63) | TRPA1CA1CA2CA12CA7 | |
| Hydrangeaic Acid SCHEMBL5352105 | 0.90 | TTR (0.53) | TRPA1CA1CA2CA12CA7 | |
| Hydrangeaic Acid SCHEMBL12204951 | 0.90 | TTR (0.53) | TRPA1CA1CA2CA12CA7 | |
| Hydrangeaic Acid SCHEMBL5352111 | 0.90 | TTR (0.53) | TRPA1CA1CA2CA12CA7 | |
| SCHEMBL7928539 | 0.86 | TRPA1 (0.59) | TRPA1CA1CA2CA12CA7 | |
| SCHEMBL26744668 | 0.86 | TRPA1 (0.59) | TRPA1CA1CA2CA12CA7 | |
| SCHEMBL20594072 | 0.83 | LCK (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL20333014 | 0.83 | RELA (0.51) | CA1CA2CA12CA7CA9 | |
| SCHEMBL26639076 | 0.83 | RELA (0.51) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410116-B2 | Compounds and use thereof in methods of treatment | THE UNIVERSITY OF QUEENSLAND (AU) | 2025-09-09 | — | — | US | disclosed |
| US-20240002326-A1 | COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT | THE UNIVERSITY OF QUEENSLAND (AU) | 2024-01-04 | — | — | US | disclosed |
| US-20230355557-A1 | ANTIVIRAL SOX INHIBITORS | GERTRUDE BIOMEDICAL PTY LTD (AU) | 2023-11-09 | — | — | US | disclosed |
| US-20230355557-A1 | ANTIVIRAL SOX INHIBITORS | GERTRUDE BIOMEDICAL PTY LTD (AU) | 2023-11-09 | — | — | US | disclosed |
| US-20230100768-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-03-30 | — | — | US | disclosed |
| US-11434190-B2 | Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-09-06 | — | — | US | disclosed |
| WO-2022040719-A1 | ANTIVIRAL SOX INHIBITORS | GERTRUDE BIOMEDICAL PTY LTD (AU) | 2022-03-03 | — | — | WO | disclosed |
| US-20190337880-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-11-07 | — | — | US | disclosed |
| US-20190337880-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | THE UNIVERSITY OF QUEENSLAND (AU) | 2019-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337880-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS-AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | SOX18, PROX1, RUNX1 | TRPA1 4843/4885CA1 4269/4885CA2 3035/4885 |
| US-11434190-B2 | Inhibitors of SOX18 protein activity for treating angiogenesis-and/or lymphangiogenesis-related diseases | SOX18, PROX1, RUNX1 | TRPA1 4843/4885CA1 4269/4885CA2 3035/4885 |
| US-20230100768-A1 | INHIBITORS OF SOX18 PROTEIN ACTIVITY FOR TREATING ANGIOGENESIS AND/OR LYMPHANGIOGENESIS-RELATED DISEASES | SOX18, PROX1, RUNX1 | TRPA1 4843/4885CA1 4300/4885CA2 3027/4885 |
| US-20230355557-A1 | ANTIVIRAL SOX INHIBITORS | SOX18, IRF3, YBX1 | TRPA1 4591/4885CA1 3889/4885CA2 3290/4885 |
| US-12410116-B2 | Compounds and use thereof in methods of treatment | SOX18, PROX1, RUNX1 | TRPA1 4838/4885CA1 3343/4885CA2 2918/4885 |
| US-20240002326-A1 | COMPOUNDS AND USE THEREOF IN METHODS OF TREATMENT | SOX18, PROX1, RUNX1 | TRPA1 4838/4885CA1 3343/4885CA2 2918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.